Pfizer announced yesterday that it has agreed to acquire the privately held antibody optimization company Bioren. Financial terms of the deal were not disclosed.
"The acquisition of Bioren strengthens Pfizer's commitment to the antibody space," said Nick Saccomano, Pfizer senior vice president for worldwide research technology, in a statement. "The ability to use and develop these technologies will help Pfizer identify new antibody leads as well as improve current antibodies in development."
Bioren is based in San Carlos, Calif.